Eosinophilic esophagitis: Management and pharmacotherapy

Paola De Angelis, G. Morino, A. Pane, F. Torroni, P. Francalanci, T. Sabbi, F. Foschia, T. Caldaro, G. Federici di Abriola, L. Dall'Oglio

Research output: Contribution to journalArticle


Eosinophilic esophagitis represents the most debated disease of the last 10 years, too often speculated or overestimated and certainly well known and examined. The aim of this study was to summarize the recent therapeutic trends in order to show persistent doubts regarding several debated therapies. The study combined the most recent international literature and the authors' daily experience to define the scope of the review, with limits caused by a lack of available randomized studies between dietetic and pharmacological treatment. It was concluded that eosinophilic esophagitis is an immunoallergic disease that is generally caused by identifiable food and environmental allergens although, in a minority of cases, the etiological trigger remains undetermined. Therapy usually fights the responsible agents, but sometimes they are not resolved. A need for more pathogenetically driven treatments is invoked.

Original languageEnglish
Pages (from-to)731-740
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Issue number5
Publication statusPublished - Apr 2008


  • Elemental diet
  • Eosinophilic esophagitis
  • Fluticasone propionate
  • Mepolizumab
  • Methylprednisolone
  • Montelukast
  • Prednisone
  • Restricted diet

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Eosinophilic esophagitis: Management and pharmacotherapy'. Together they form a unique fingerprint.

  • Cite this